Edition:
United States

Calithera Biosciences Inc (CALA.OQ)

CALA.OQ on NASDAQ Stock Exchange Global Select Market

5.93USD
23 Apr 2018
Change (% chg)

$-0.17 (-2.87%)
Prev Close
$6.10
Open
$6.10
Day's High
$6.15
Day's Low
$5.93
Volume
51,080
Avg. Vol
111,070
52-wk High
$20.00
52-wk Low
$5.38

Select another date:

Wed, Apr 18 2018

BRIEF-Calithera Biosciences Announces FDA Fast Track Designation Granted To CB-839 In Combination With Cabozantinib For Treatment Of Patients With Advanced Renal Cell Carcinoma

* CALITHERA BIOSCIENCES ANNOUNCES FDA FAST TRACK DESIGNATION GRANTED TO CB-839 IN COMBINATION WITH CABOZANTINIB FOR TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA Source text for Eikon: Further company coverage:

BRIEF-Calithera Biosciences Qtrly Net Loss From Operations $11.0 Mln

* CALITHERA BIOSCIENCES REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

BRIEF-Calithera Biosciences Says Plans To Initiate A Global, Randomized Phase 2 Trial Of CB-839 In Combination With Cabozantinib In Q2 Of 2018

* CALITHERA BIOSCIENCES INC - PLAN TO INITIATE A GLOBAL, RANDOMIZED PHASE 2 TRIAL OF CB-839 IN COMBINATION WITH CABOZANTINIB IN Q2 OF 2018 Source text for Eikon: Further company coverage:

BRIEF-Calithera Biosciences expands clinical collaboration with Bristol-Myers Squibb

* Initial results from Phase 2 study of CB-839 in combination with opdivo® (nivolumab) to be presented at the Society for Immunotherapy of Cancer Meeting

BRIEF-Calithera Biosciences Q3 operating loss per share $0.17

* Calithera biosciences reports third quarter 2017 financial results and recent highlights

Select another date: